Do CymaBay Therapeutics Inc. (CBAY) beta value of 1.22 signposts another twist? – Invest Chronicle

Do CymaBay Therapeutics Inc. (CBAY) beta value of 1.22 signposts another twist?

CymaBay Therapeutics Inc. (CBAY) is priced at $4.29 after the most recent trading session. At the very opening of the session, the stock price was $3.823 and reached a high price of $4.38, prior to closing the session it reached the value of $3.94. The stock touched a low price of $3.81.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Recently in News on May 11, 2021, CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of an inducement award to Lewis Stuart in connection with his appointment as the company’s Chief Commercial Officer. The Compensation Committee of the Board of Directors of CymaBay approved the grant of a non-qualified stock option to purchase an aggregate of 360,000 shares of its common stock as an inducement material to Mr. Stuart entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the applicable award agreement covering such grant. You can read further details here


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


CymaBay Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $6.73 on 01/12/21, with the lowest value was $3.81 for the same time period, recorded on 05/11/21.

CymaBay Therapeutics Inc. (CBAY) full year performance was 133.15%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CymaBay Therapeutics Inc. shares are logging -52.65% during the 52-week period from high price, and 141.01% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.78 and $9.06.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1083443 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics Inc. (CBAY) recorded performance in the market was -25.26%, having the revenues showcasing -30.36% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 288.67M, as it employees total of 44 workers.

Market experts do have their say about CymaBay Therapeutics Inc. (CBAY)

During the last month, 11 analysts gave the CymaBay Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.21, with a change in the price was noted -3.00. In a similar fashion, CymaBay Therapeutics Inc. posted a movement of -41.15% for the period of last 100 days, recording 1,117,525 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CBAY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of CymaBay Therapeutics Inc. (CBAY)

Raw Stochastic average of CymaBay Therapeutics Inc. in the period of last 50 days is set at 32.43%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 51.61%. In the last 20 days, the company’s Stochastic %K was 29.18% and its Stochastic %D was recorded 24.61%.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Bearing in mind the latest performance of CymaBay Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -25.26%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -45.35%, alongside a boost of 133.15% for the period of the last 12 months. The shares increased approximately by 0.47% in the 7-day charts and went down by 2.39% in the period of the last 30 days. Common stock shares were lifted by -30.36% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam